Approximately 30–40% of patients treated with radical prostatectomy (RP) for clinically localized prostate cancer will experience disease progression indicated by rising post-surgery serum prostate specific antigen (PSA) levels. This evidence concerns the gene KLK3 and Familial prostate cancer.